Please use this identifier to cite or link to this item:
|Title:||Improvement in rheumatoid heart disease following infliximab in a patient with long standing rheumatoid arthritis|
Rheumatoid heart disease
Tumour necrosis factor
|Source:||Hon, Y.K. (2004-09). Improvement in rheumatoid heart disease following infliximab in a patient with long standing rheumatoid arthritis. APLAR Journal of Rheumatology 7 (2) : 133-135. ScholarBank@NUS Repository. https://doi.org/10.1111/j.1479-8077.2004.00091.x|
|Abstract:||This report describes a 60-year-old woman with chronic active rheumatoid arthritis (RA) with rheumatoid heart disease treated successfully with infliximab. The patient had a history of rheumatoid heart disease, presented with cardiac failure and also had active polyarthritis. Two-dimensional echocardiogram (2-DE) showed ejection fraction (EF) of 35%. Infliximab therapy at 3 mg/kg was given to the patient, at weeks 0, 2, and 6 and then 8-weekly There was complete remission of her joint symptoms and the EF improved to 55%. Patients with active arthritis and rheumatoid heart disease can benefit from infliximab. ©Asia Pacific League of Associations for Rheumatology.|
|Source Title:||APLAR Journal of Rheumatology|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 21, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.